In part one, Alan Wein is joined by Melissa Kaufman, who chaired the AUA Guideline Committee on Genitourinary Syndrome of Menopause (GSM), to discuss these guidelines. Dr. Kaufman emphasizes the ...

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

EVOLUTION study, lutetium PSMA-617, prostate cancer immunotherapy, checkpoint inhibitors, metastatic castration-resistant prostate cancer, EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA ...

Alan Bryce hosts Mary-Ellen Taplin to discuss key recommendations from the 2024 US Prostate Cancer Consensus Conference addressing biochemical recurrence management. Dr. Taplin emphasizes that PSMA ...

Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity ...

DARPin radioligand therapy, lead-212 radiopharmaceuticals, DLL3 targeted therapy, alpha particle therapy, DARPin-Based Radioligand Therapy Targets DLL3 with Lead-212 for Cancer Treatment with Philippe ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

HIF-2 inhibitor kidney cancer, Casdatifan cabozantinib combination, refractory renal cell carcinoma treatment, AB-521 clinical trial, clear cell RCC therapy, Combination HIF-2α/VEGF Dual Inhibition in ...

CHAI biomarker, using AI to predict BCG vs Gem/Doce response in bladder cancer, achieving 90% success rate, insights on precision medicine, Computational Histology AI Guides Treatment Selection for ...

ENZAMET study, IGF-1 cytokines and sphingolipids as prognostic factors in mHSPC, precision metabolic therapy trials, Exploring IGF-1 Pathway Biomarkers and Outcomes in Metastatic Hormone-Sensitive ...